Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration
- 1 June 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (6), 2596-2602
- https://doi.org/10.1128/aac.01540-09
Abstract
Sulfobutylether-beta-cyclodextrin (SBECD), a large cyclic oligosaccharide that is used to solubilize voriconazole (VRC) for intravenous administration, is eliminated mainly by renal excretion. The pharmacokinetics of SBECD and voriconazole in patients undergoing extracorporeal renal replacement therapies are not well defined. We performed a three-period randomized crossover study of 15 patients with end-stage renal failure during 6-hour treatment with Genius dialysis, standard hemodialysis, or hemodiafiltration using a high-flux polysulfone membrane. At the start of renal replacement therapy, the patients received a single 2-h infusion of voriconazole (4 mg per kg of body weight) solubilized with SBECD. SBECD, voriconazole, and voriconazole- N -oxide concentrations were quantified in plasma and dialysate samples by high-performance liquid chromatography (HPLC) and by HPLC coupled to tandem mass spectrometry (LC-MS-MS) and analyzed by noncompartmental methods. Nonparametric repeated-measures analysis of variance (ANOVA) was used to analyze differences between treatment phases. SBECD and voriconazole recoveries in dialysate samples were 67% and 10% of the administered doses. SBECD concentrations declined with a half-life ranging from 2.6 ± 0.6 h (Genius dialysis) to 2.4 ± 0.9 h (hemodialysis) and 2.0 ± 0.6 h (hemodiafiltration) ( P < 0.01 for Genius dialysis versus hemodiafiltration). Prediction of steady-state conditions indicated that even with daily hemodialysis, SBECD will still exceed SBECD exposure of patients with normal renal function by a factor of 6.2. SBECD was effectively eliminated during 6 h of renal replacement therapy by all methods, using high-flux polysulfone membranes, whereas elimination of voriconazole was quantitatively insignificant. The SBECD half-life during renal replacement therapy was nearly normalized, but the average SBECD exposure during repeated administration is expected to be still increased.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy of contraceptive methods: A review of the literatureThe European Journal of Contraception & Reproductive Health Care, 2010
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetic Analysis of Carboplatin and Etoposide in a Small Cell Lung Cancer Patient Undergoing HemodialysisJournal of Thoracic Oncology, 2008
- Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended DosingClinical Journal of the American Society of Nephrology, 2008
- Administration of Tobramycin in the Beginning of the Hemodialysis SessionClinical Journal of the American Society of Nephrology, 2007
- Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPSKidney International, 2006
- Antimykotika unter kontinuierlicher NierenersatztherapieMycoses, 2005
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- Fluorescence determination of sulphobutylether-β-cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formationJournal of Pharmaceutical and Biomedical Analysis, 2000
- Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and StabilizationJournal of Pharmaceutical Sciences, 1996